Stocktoria

Tarsus Pharmaceuticals, Inc. TARS

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Chart by TradingView
4/9
Piotroski F — financial health
2.84
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$451.4M$183.0M$17.4M$25.8M$57.0M
Operating income-$71.0M-$120.6M-$143.2M-$62.7M-$12.2M
Net income-$66.4M-$115.6M-$135.9M-$62.1M-$13.8M
Operating cash flow-$12.5M-$83.0M-$117.5M-$49.0M$3.7M
Free cash flow-$22.3M-$84.6M-$119.0M-$49.5M$3.2M
Total assets$562.2M$377.0M$265.5M$227.9M$178.9M
Total liabilities$218.7M$152.5M$68.5M$35.0M$12.2M
Shareholders' equity$343.4M$224.5M$197.0M$192.9M$166.7M
Ratios
Operating margin-15.7%-65.9%-820.5%-242.9%-21.3%
Net margin-14.7%-63.2%-778.9%-240.5%-24.2%
FCF margin-4.9%-46.2%-682.0%-191.9%5.5%
Return on assets-11.8%-30.7%-51.2%-27.2%-7.7%
Return on equity-19.3%-51.5%-69.0%-32.2%-8.3%
Debt / equity0.21×0.32×0.15×0.10×0.00×
Current ratio3.854.426.9314.6115.33
Revenue growth146.7%948.6%-32.4%-54.7%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.226,251$15.9M
RENAISSANCE TECHNOLOGIES LLC73,400$5.1M

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 2.84 (safe)

  • Working capital / assets 0.689
  • Retained earnings / assets -0.759
  • EBIT / assets -0.126
  • Equity / liabilities 1.57

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001819790 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.